Research and Markets (http://www.researchandmarkets.com/research/806dd2/paroxysmal_nocturn) has announced the addition of new report "Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.

It is estimated that the Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market in the seven key markets of the US, the UK, Germany, Italy, France, Spain and Japan was worth $758.3m in 2011 and is forecast to grow at a compound annual growth rate (CAGR) of 4.8% to reach $1,104m by 2019. The current market is strong and dominated by the only approved drug - Soliris (eculizumab) from Alexion Pharmaceuticals. The growth during 2006-2011 is primarily attributed to the launch of Soliris in 2007 in both the US and Europe.

This report is an essential source of information and analysis on the global Paroxysmal Nocturnal Hemoglobinuria Therapeutics market. It identifies the key trends shaping and driving the global Paroxysmal Nocturnal Hemoglobinuria Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.

Most importantly, the report provides valuable insights on the pipeline products within the global Paroxysmal Nocturnal Hemoglobinuria Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Scope:

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Paroxysmal Nocturnal Hemoglobinuria Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Paroxysmal Nocturnal Hemoglobinuria Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Paroxysmal Nocturnal Hemoglobinuria Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Paroxysmal Nocturnal Hemoglobinuria Therapeutics market

Key Topics Covered:

• Paroxysmal Nocturnal Hemoglobinuria Therapeutics - Introduction
• Paroxysmal Nocturnal Hemoglobinuria Therapeutics - Market Characterization
• Paroxysmal Nocturnal Hemoglobinuria Therapeutics - Competitive Assessment
• Paroxysmal Nocturnal Hemoglobinuria Therapeutics - Pipeline Assessment
• Paroxysmal Nocturnal Hemoglobinuria Therapeutics - Clinical Trials Mapping
• Paroxysmal Nocturnal Hemoglobinuria Therapeutics - Strategic Assessment
• Paroxysmal Nocturnal Hemoglobinuria Therapeutics - Future Players in the Market

For more information visit http://www.researchandmarkets.com/research/806dd2/paroxysmal_nocturn